Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).

作者信息

George Jacob, Lau George, Kawaguchi Takumi, Fan Jian-Gao, Ji-Dong Jia, Wang Fu-Sheng, Kumar Manoj, Sarin Shiv Kumar, Omata Masao, Wong Vincent Wai-Sun, Eslam Mohammed

机构信息

Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia.

Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong Special Administrative Region, Hong Kong, China.

出版信息

Hepatol Int. 2023 Jun;17(3):546-549. doi: 10.1007/s12072-023-10530-z. Epub 2023 Apr 20.

DOI:10.1007/s12072-023-10530-z

PMID:37081251

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10224827/

Abstract

摘要

相似文献

[1]

Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).

Hepatol Int. 2023-6

[2]

MAFLD, patient-centred care, and APASL.

Hepatol Int. 2022-10

[3]

Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.

Nutrients. 2021-3-21

[4]

Metabolic dysfunction associated fatty liver disease (MAFLD) and serum vitamin D concentration in South Korea.

Asia Pac J Clin Nutr. 2022

[5]

Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.

Hepatol Int. 2022-12

[6]

Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.

Liver Int. 2023-3

[7]

Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.

Front Public Health. 2023

[8]

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)-A Review.

Nutrients. 2021-7-30

[9]

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.

J Gastroenterol. 2021-11

[10]

Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease.

J Clin Endocrinol Metab. 2022-7-14

引用本文的文献

[1]

HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients.

Sci Rep. 2025-8-24

[2]

HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians.

Pak J Med Sci. 2025-3

本文引用的文献

[1]

Microbiome-derived ethanol in nonalcoholic fatty liver disease.

Nat Med. 2022-10

[2]

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Nat Rev Gastroenterol Hepatol. 2022-10

[3]

A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.

Hepatol Int. 2022-8

[4]

Impact of non-invasive biomarkers on hepatology practice: Past, present and future.

J Hepatol. 2022-6

[5]

Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.

Hepatobiliary Pancreat Dis Int. 2022-4

[6]

Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.

Clin Transl Gastroenterol. 2022-1-12

[7]

The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.

J Dig Dis. 2022-1

[8]

Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.

J Diabetes Investig. 2022-2

[9]

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.

J Hepatol. 2021-12

[10]

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.

Lancet Gastroenterol Hepatol. 2021-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献